Aditxt signs second amendment to arrangement agreement with Appili Therapeutics
60% off Profit Pro - Limited Time Offer!
3.15MUSD
Type
Common Stock
Exchange
PINK
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
CA03783R1073
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
March
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
-0.09
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.02
Wall Street Target Price
0.15
EPS Estimate Current Year
0
EPS Estimate Next Year
0
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
827,407
Gross Profit TTM
1,390,684
EBITDA
-8,590,420
Profit Margin
0.00%
Return On Assets TTM
-244.22%
Return On Equity TTM
-938.72%
Revenue Per Share TTM
0.007
Qtly Revenue Growth YOY
-96.50%
Diluted Eps TTM
-0.02
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
1
Price Sales TTM
9.3018
Price Book MRQ
1.4792
Enterprise Value Revenue
28
Enterprise Value EBITDA
-2
88.70
1.04%409.80
0.46%632.04
0.33%716.68
0.31%630.00
0.00%173.50
0.00%198.28
0.00%99.02
-0.96%241.31
-0.88%113.30
-0.54%Aditxt signs second amendment to arrangement agreement with Appili Therapeutics
Aditxt signs agreement to acquire Appili Therapeutics